Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01582477 · ClinicalTrials.gov registry record · Phase 4
TAP-patients With Robotic Assisted Lap Prostatectomy
A Phase 4 study of Analgesia and Post-surgical Pain, sponsored by Pacira Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT01582477: Completed Phase 4 study of Analgesia and Post-surgical Pain, sponsored by Pacira Pharmaceuticals.
NCT01582477 is a Phase 4 study of Analgesia and Post-surgical Pain that has completed, run by Pacira Pharmaceuticals. The registered enrollment target is 24 participants, below the 92-participant average among 19 other Analgesia trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01582477, a Phase 4 study of Analgesia and Post-surgical Pain, has completed, sponsored by Pacira Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to assess the safety and efficacy of EXPAREL when administered via infiltration into the transversus abdominis plane (TAP) to prolonged postsurgical analgesia in men undergoing robot-assisted laparoscopic prostatectomy.
Conditions Studied
Interventions
- DRUG EXPAREL 20 mL
- DRUG EXPAREL 40 mL
Study Locations (1)
Massachusetts
- Steward St. Elizabeth's - Brighton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2012-03 |
| Est. Completion | 2012-07 |
| Phase | Phase 4 |
What the finished NCT01582477 record still lists
NCT01582477 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 92-participant average among 19 other Analgesia trials with a reported enrollment target (74% lower).
The record links to 3 conditions, with Analgesia appearing as the primary indexed condition, and to 2 interventions - of which EXPAREL 20 mL is the first listed.
NCT01582477 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01582477 about?
NCT01582477 is a clinical study titled "TAP-patients With Robotic Assisted Lap Prostatectomy". The purpose of the study is to assess the safety and efficacy of EXPAREL when administered via infiltration into the transversus abdominis plane (TAP) to prolonged postsurgical analgesia in men undergoing robot-assisted laparoscopic prostatectomy.
What is the current status of trial NCT01582477?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2012-03. Estimated completion is 2012-07.
What conditions does trial NCT01582477 study?
This clinical trial studies the following conditions: Analgesia, Post-surgical Pain, Prostatectomy.
What interventions are being tested in trial NCT01582477?
The interventions under investigation include: EXPAREL 20 mL (DRUG), EXPAREL 40 mL (DRUG).
Who is sponsoring clinical trial NCT01582477?
This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01582477 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Analgesia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01582477's enrollment target sits among peer trials
24 20th of 19 the lowest of 19 other Analgesia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Analgesia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Adductor Canal Block and IPACK Block vs. Isolated Adductor Canal Block for Post-Operative Analgesia Following HTO/DFO/TTO
RECRUITING · Phase 4
-
Transversus Abdominis Plane Block Compared to Local Anesthetic Wound Infiltration in Gynecologic Oncology Surgery
RECRUITING · Phase 4
-
Evaluation of the Effects of Ketorolac Dose on Duration of Analgesia in Emergency Department (ED) Renal Colic Patients
RECRUITING · Phase 4
-
Low-dose Buccal Buprenorphine: Relative Abuse Potential and Analgesia
RECRUITING · Phase 4
-
Pecto-intercostal Fascial Block (PIFB) for Postop Analgesia Following Sternotomy in Cardiac Surgery Patients
COMPLETED · Phase 4
-
Benzocaine Versus Placebo Spray for Pain Relief at Hysterosalpingogram
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia